May 29, 2015

Dear Medical Director:

The American Academy of Pediatrics (AAP), dedicated to the health of infants, children and adolescents, recently released updated guidance on Human Papillomaviruses (HPV). The updated guidelines are published in the 2015 AAP Red Book (HPV Chapter).

The guidance provided in the 2015 AAP Red Book HPV chapter replaces the 2012 AAP Policy Statement: HPV Vaccine Recommendations. We ask that your plan benefits coverage for HPV be updated to reflect the latest recommendations.

The American Academy of Pediatrics and the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommend HPV9, HPV4, or HPV2 vaccine for routine immunization of females 11 or 12 years of age, and recommend either HPV9 or HPV4 for routine immunization of males 11 or 12 years of age. The vaccination series can be started as young as 9 years of age, and in the case of sexual abuse, HPV vaccination is recommended beginning at 9 years of age. The HPV9, HPV4, and HPV2 vaccines also are recommended for females 13 through 26 years of age not previously immunized. HPV9 and HPV4 also are recommended for males 13 through 21 years of age not previously immunized. Males 22 through 26 years of age may be immunized with HPV9 or HPV4, and both are recommended for men who have sex with men and people who are immunocompromised (including those with HIV infection) through 26 years of age. HPV vaccines are not licensed for use in people older than 26 years of age.

The AAP HPV recommendations may be accessed at:  

On behalf of our nation’s children and the over 62,000 members of the AAP, health plans and employers are encouraged to provide benefits coverage for recommended pediatric services. In addition, there should be adequate payment for the vaccine. Appropriate vaccine payments need to account not only for the vaccine cost, but also need to adequately cover the costs of ordering, storage, insurance, etc. as outlined in the attached Business Case for Pricing Vaccines. Inadequate payment for vaccines creates a barrier to accessing appropriate medical care. Lack of access to preventive care services leads to more costly medical interventions borne by the family, patient, health insurance plan and employer.

If you need any additional information on this policy, please contact Jennifer Frantz, MPH, AAP Manager, Committee on Infectious Diseases at jfrantz@aap.org or 800/433-9016 ext 7939.

Sincerely,

/S/

Sandra G. Hassink, MD, FAAP
President

SGH/it
Enclosure:  The Business Case for Pricing Vaccines
The Business Case for Pricing Vaccines
Revised March 2012

One of the goals of the American Academy of Pediatrics (AAP), shared by the American Academy of Family Physicians (AAP) and the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), is to promote maximum immunization coverage for all infants, children, adolescents, and young adults. To achieve this goal, physicians must be paid for the full costs (direct and indirect) of vaccine product-related expenses and vaccine administration expenses as well as the margin for overall overhead expenses. Because the private physician practice is the backbone of the immunization delivery infrastructure, public and private sector payers must recognize that a pediatric practice is really a business entity and must run on sound, generally accepted business principles to remain viable. Vaccines are among the top overhead expenses for the pediatric practice. Therefore, payments must ensure recovery of the total direct and indirect practice expenses and a margin for both the vaccine product and the vaccine administration office costs and the time spent counseling families on the indications for and potential adverse effects of each vaccine product.

The number of vaccines continues to increase and the costs have become increasingly high, necessitating a more business-like approach to payment because of the increased potential for uncompensated costs. For most states, which are non-universal purchase, the direct and indirect expenses in maintaining the vaccine product must be accounted for in a compensation formula that incorporates these factors in the vaccine purchase as well as a margin to incentivize immunizations. For universal purchase states, this means having an acceptable immunization administration fee that also covers compensation for indirect vaccine acquisition and maintenance expenses as there are no direct vaccine purchase costs and no mechanism for paying indirect expenses.

Several studies published in the Pediatrics supplement, “Financing of Childhood and Adolescent Vaccines,“ underscore the need for appropriate payment to cover the total costs for immunizations. In one major study, a cross-sectional survey of private practices in 5 states (California, Georgia, Michigan, New York, and Texas) concluded that there is a wide variation in payment for vaccines and administration fees by payers, resulting in the “need for providers to seek opportunities to reduce costs and increase reimbursements.”

Vaccine Product-Related Expenses: This is separately reportable from the immunization administration. Some payers mistakenly try to maintain that inadequate vaccine payments can be made up by nominal immunization administration fees. However, these are two separate expenses, and both need to be appropriately covered by payers. The payment for vaccines is a legitimate expense that must cover the total direct and indirect expenses as listed below.

1. Purchase price (acquisition cost) of the vaccine: This is the amount paid by the physician for the vaccine. Although discounts may exist, these are not available to all pediatric practices and may be time limited. An accurate and verifiable public source on the current manufacturer’s price for vaccines can be accessed on the CDC vaccine price list for the private sector at: [http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm](http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm) The AAP believes that the CDC private payer vaccine price list should be used as a transparent methodologic basis for vaccine acquisition and invoice cost as part of the total cost of the vaccine.

2. Personnel costs for ordering and inventory: Medical office staff (clinical and administrative) time to monitor vaccine stock; place orders; negotiate costs, delivery, and payment terms; and ensure safe storage procedures (locks, alarms, temperature controls, etc)
3. **Storage costs:** Vaccines must be stored at very specific temperature ranges and, therefore, require special monitoring and storage equipment. The practice expense component of the total immunization administration code pays for part of the vaccine storage costs; however, there are certain expenses that are **not** included that must be compensated: freezer(s), freezer lock(s), freezer alarm system(s), and generators for continued electrical supply (all of which are depreciated).

4. **Insurance against loss of the vaccine:** Professional liability malpractice insurance does not cover vaccine product, so additional insurance coverage is needed by the practice.

5. **Recovery of costs attributable to inventory shrinkage, wastage, and nonpayment:** In the retail market, inventory shrinkage refers to the uncompensated loss of product due to theft, vendor error, and administrative error. Additionally, there is an estimated wastage/nonpayment of at least 5% (this should be accurately accounted for in each office). This includes drawing up the vaccine and having the patient/family reconsider and refuse, resulting in subsequent nonpayment, or a loss of dose that may occur in attempting to vaccinate an uncooperative/combative patient. This would also include collection costs in response to nonpayment by the patient or third-party payer.

6. **Lost opportunity costs:** This is the cost of maintaining a large vaccine inventory. Between $10,000 and $15,000 in inventory is maintained per pediatrician or other provider of vaccines. Every business with this level of money tied up in product inventory must receive an appropriate return on its investment, and so should every pediatric practice.

When the direct and indirect expenses are totaled for the vaccine product, estimates range from 17% to 28% depending on the practice. Therefore, payments for the vaccine should be at the level that covers the total vaccine expenses. So what would be appropriate payment for vaccine product expenses for the total direct and indirect costs? Payments must:

- Be free of any discounts and based on a transparent and verifiable data source, such as the CDC vaccine price list for the private sector, available at: [http://www.cdc.gov/vaccines/programs/vfc/cdc-vacc-price-list.htm](http://www.cdc.gov/vaccines/programs/vfc/cdc-vacc-price-list.htm).
- Cover the vaccine product purchase price as well as all related office expenses as noted above and a return on the investment for the dollars invested in vaccine inventory.
- Be at least 125% of the current CDC vaccine price list for the private sector.

Pediatric practices are the public health infrastructure for the nation’s childhood immunization program. It is imperative to incentivize pediatricians to participate in immunization efforts by appropriate payment for vaccines.

---

**References**

1. Financing of Childhood and Adolescent Vaccines. *Pediatrics*. 2009;124(Suppl 5). Available at: [http://pediatrics.aappublications.org/content/vol124/Supplement_5/](http://pediatrics.aappublications.org/content/vol124/Supplement_5/)